Aytu BioPharma Acquires License to Develop DB102 for vEDS

Aytu BioPharma Acquires License to Develop DB102 for vEDS

292286

Aytu BioPharma Acquires License to Develop DB102 for vEDS

Aytu BioPharma has acquired the option to license DB102 (enzastaurin), an investigational anti-tumor therapy with the potential to treat vascular Ehlers-Danlos syndrome, or vEDS. Denovo Biopharma, which holds worldwide rights to DB102 — originally developed as an oncology treatment — will continue to develop the oral therapy for certain cancers. “DB102 has the potential to treat a variety of disorders, both inside and outside of the oncology field,” Michael F. Haller, PhD, Denovo’s chief business…

You must be logged in to read/download the full post.